Innovation

More Topics

Male being kept up at night and unable to sleep

Interest rates, IPOs, China, or Trump: What’s keeping investors up at night?Interest rates, IPOs, China, or Trump: What’s keeping investors up at night?

Sentiment is relatively positive following some turbulent years, but macro-economic issues are worrying investors, according to an analyst from William Blair.

byDan Stanton, Editorial director

Feb 20, 2025

|

1 Min Read

Asia map on the globe

Eyes on Asia: Bain Capital buys MTPC, Merck & Co. halts HPV vax, and Illumina Eyes on Asia: Bain Capital buys MTPC, Merck & Co. halts HPV vax, and Illumina

byMillie Nelson

Feb 18, 2025

1 Min Read

headshot of Janeé Pelletier, chief marketing officer at Learning Undefeated.

‘Houston, we have a talent problem!’ TMC taps up next gen of biopharma experts ‘Houston, we have a talent problem!’ TMC taps up next gen of biopharma experts

byMillie Nelson

Feb 6, 2025

1 Min Read

Eyes on Asia: Ascentage’s IPO, Arrivent & Lepu, Sanofi approval, and more Eyes on Asia: Ascentage’s IPO, Arrivent & Lepu, Sanofi approval, and more

byMillie Nelson

Feb 3, 2025

1 Min Read

Word writing text Science. Business concept for Study of physical world structure behavior Experimental research

Scientific advances only succeed if they are embraced, says report Scientific advances only succeed if they are embraced, says report

byLisa Henderson

Jan 22, 2025

1 Min Read

Asia on a world globe

Eyes on Asia: AZ C-suite, Verdiva and Sciwind, Korea and China at JPM Eyes on Asia: AZ C-suite, Verdiva and Sciwind, Korea and China at JPM

Jan 21, 2025

1 Min Read

magnifying glass focused on China flag

China biopharma development still hot & still expanding its reach

China biopharma development still hot & still expanding its reach

byRichard Daverman, Editor

Image of China banknotes with a magnifying glass indicating dealmaking in Asia

Eyes on Asia: BIOSECURE, Merck & Hansoh, Roche adds ADC, and Samsung

Eyes on Asia: BIOSECURE, Merck & Hansoh, Roche adds ADC, and Samsung

byDan Stanton, Editorial director

Charles River launches UK incubator program

Charles River launches UK incubator program

byMillie Nelson, Editor

Hervé Ansanay, Biotech Alliance Manager, discusses the features of the RESEAU SATT - SATT NETWORK

Sponsored Content

RESEAU SATT, the Best of French Deep Tech

RESEAU SATT, the Best of French Deep Tech

byBIO-Europe 2024

Michael May, PhD, President, CCRM discusses Canada as a place for life sciences in this video.

Bridging AI & Life Sciences, Why Investing in Canada Should Be Your Next Move

Bridging AI & Life Sciences, Why Investing in Canada Should Be Your Next Move

byBIO-Europe 2024

Asia currency

Eyes on Asia: Sanofi expands China footprint; Takeda buys anemia asset

Eyes on Asia: Sanofi expands China footprint; Takeda buys anemia asset

byRichard Daverman, Editor

China on a clock

A growing phenomenon: The rise of biopharma NewCos in China

A growing phenomenon: The rise of biopharma NewCos in China

byRichard Daverman, Editor

Berlin on written wooden block

Bayer expands global incubator network with Germany hub

Bayer expands global incubator network with Germany hub

byMillie Nelson, Editor

Data

To protect the future of healthcare, we need to be data-driven

To protect the future of healthcare, we need to be data-driven

byMillie Nelson, Editor

The ELA'S 2024

LSX awards the crème de la crème of dealmaking

LSX awards the crème de la crème of dealmaking

byMillie Nelson, Editor

Money

Eyes on Asia: GSK’s $300m lupus bet, Pfizer’s $1bn China blast

Eyes on Asia: GSK’s $300m lupus bet, Pfizer’s $1bn China blast

byRichard Daverman, Editor

coloured pencils

Nonprofit looks to bring tomorrow’s science into today’s classrooms

Nonprofit looks to bring tomorrow’s science into today’s classrooms

byMillie Nelson, Editor

Europe’s aversity to risk is why the US is ahead, say experts

Europe’s aversity to risk is why the US is ahead

byMillie Nelson, Editor

Money

Eyes on Asia: VC hits China, BioStar IPO, and Legend splits from GenScript

Eyes on Asia: VC hits China, BioStar IPO, and Legend splits from GenScript

byRichard Daverman, Editor

Eddingpharm reverse-merger ‘breakthrough’ for Hong Kong stock exchange

Eddingpharm reverse-merger ‘breakthrough’ for Hong Kong stock exchange

byRichard Daverman, Editor

Asian currency

Eyes on Asia: Astellas bags gene therapy, AZ a lipoprotein, and a Japanese incubator

Astellas bags gene therapy, AZ a lipoprotein, and a Japanese incubator

byRichard Daverman, Editor

From east to west: Lilly plans incubators in China and UK

From east to west: Lilly plans incubators in China and UK

byMillie Nelson, Richard Daverman

Green leaf with sustainability symbol

Business Strategy

The sustainability series: Reflect, rethink, and reform

The sustainability series: Reflect, rethink, and reform

byMillie Nelson, Editor

Novo’s hunt for genetic med tech drove $600m NanoVation pact

Novo’s hunt for genetic med tech drove $600m NanoVation pact

byMillie Nelson, Editor

Eyes on Asia: News from Sanofi, Bayer, AZ plus the return of VC?

News from Sanofi, Bayer, AZ plus the return of VC?

byRichard Daverman, Editor

Eyes on Asia: Shinyaku’s $735m DMD deal, Kite turns back in China, and more

Shinyaku’s $735m DMD deal, Kite turns back in China, and more

byRichard Daverman, Editor

photo of a sunrise over solar panels/building

Inside five innovative research companies driving progress in oncology and neurology

Driving progress in oncology and neurology

Chinese flag — Photo

China biopharma faces a pause; how bad is it?

China biopharma mid-2023 market summary

byRichard Daverman, Editor

Illustration, Science word. Business concept for Study of physical world structure behavior Experimental research — Illustration

European drug discovery and development players showcase their science at BIO-Europe 2023

European drug discovery and development players showcase their science

Plenary at BIO-Europe in Munich

How industry trends are evolving biotech innovation in 2023

2023 industry trends that helped evolve biotech innovation

three member panel on stage

‘Data matters most’ in biotech, and AI is here to help

‘Data matters most’ in biotech, and AI is here to help

lab testing with vials closeup

Early 2024 review of biotech funding and innovation

Early 2024 review of biotech investment and innovation

photo of panel at BIO Europe Spring 2024

Moving from eminence-based to evidence-based healthcare

Moving from eminence-based to evidence-based healthcare

Eyes on Asia: Eisai $1.5bn pact, OcuMension & Alcon, TYK IPO and more

Eyes on Asia: Eisai $1.5bn pact, OcuMension & Alcon, TYK IPO and more

byRichard Daverman, Editor

Subscribe to Our Newsletters

Stay updated and receive your insights for life sciences investment, innovation and partnering directly in your inbox.